Prosecution Insights
Last updated: November 04, 2026
Application No. 17/675,775

VARIANT FC DOMAINS AND USES THEREOF

Non-Final OA §102
Filed
Feb 18, 2022
Priority
Aug 22, 2019 — provisional 62/890,475 +13 more
Examiner
CHEONG, CHEOM-GIL
Art Unit
1645
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Cidara Therapeutics Inc.
OA Round
5 (Non-Final)
64%
Grant Probability
Moderate
5-6
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 64% of resolved cases
64%
Career Allowance Rate
125 granted / 194 resolved
+4.4% vs TC avg
Strong +53% interview lift
Without
With
+53.4%
Interview Lift
resolved cases with interview
Typical timeline
3y 4m
Avg Prosecution
34 currently pending
Career history
227
Total Applications
across all art units

Statute-Specific Performance

§101
3.3%
-36.7% vs TC avg
§103
24.6%
-15.4% vs TC avg
§102
16.1%
-23.9% vs TC avg
§112
37.6%
-2.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 194 resolved cases

Office Action

§102
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 9/3/2026 has been entered. Claim Status Claims 1-16, 18-33, 36-39, 41-62, and 65-94 were canceled. Claims 17, 34-35, 40, 63-64 and 95 are pending and under consideration. Withdrawn Rejections Objection of claim 95 is withdrawn. Applicant amended the claim 95, thereby obviating this rejection/objection. Rejection of Claim 95 under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention is withdrawn. Applicant amended the claim 95, thereby obviating this rejection/objection. Rejection of Claim(s) 17, 34-35, 40, 63-64 and 95 under 35 U.S.C. 102(a)(1) as being anticipated by Liu (WO2018107116) is withdrawn. Applicant amended the claim 17 to recite specific amino acid tyrosine at position 252, threonine at position 254, and glutamate at position 256, thereby obviating this rejection/objection. NEW - Claim Rejections - 35 USC § 102 (necessitated by amendments) The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 17 and 63 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Ellis et al (WO2013/011076; PTO-892). Regarding claims 17, Ellis teaches “The present invention provides antigen binding proteins which bind specifically to TNF-alpha. For example novel variants of anti-TNF antibodies such as adalimumab which show increased binding to the FcRn receptor or increased half life compared to adalimumab.” (abstract). Ellis teaches IgG1 heavy chain constant region/M252Y/S254T/T256E, SEQ 7 (result 13 of 1.rag). SEQ ID NO: 7 of Ellis comprises 330 amino acid which corresponds to 36.3 kDa (330 amino acid X 0.11 kDa /average amino acid) as claimed by instant claim 17. As shown below, SEQ ID NO: 7 of Ellis comprises C220/ Y252/T254/E256. As evidenced by instant specification, page 37, instant SEQ ID NO: 31 also comprises same amino acid C220/ Y252/T254/E256. As shown below, SEQ ID NO: 7 of Ellis corresponds to instant SEQ ID NO: 31 wherein Z1=N; J1=C; X1=Y; X2=T; X3=E; Z2=N; X4=L; X5=Q; X6=D; X7=L; X8=M; X9= N; Z3=K (also see page 37 of instant specification for instant SEQ ID NO: 31). result 13 of 1.rag PNG media_image1.png 814 1051 media_image1.png Greyscale Regarding claim 63, it is well known in the art that Fc region of antibody dimerizes and therefore variant Fc of Ellis comprising M252Y/S254T/T256E will also dimerize. Further, Fc of Ellis comprises Cysteine at position 220 which is responsible for disulfide bond in Fc dimer. Claim(s) 17, 34-35, and 63-64 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Chamberlain et al (US2010/0234575; PTO-892). Regarding claim 17, Chamberlain teaches Fc variants with altered binding to FcRn (title). Chamberlain teaches Human immunoglobulin G1 constant heavy chain mutein which has 330 amino acid residues (result 14 of 1.rag). As discussed above, 330 amino acid corresponds to 36.3 kDa (330 amino acid X 0.11 kDa /average amino acid) as claimed by instant claim 17. As shown below, Fc variant of Chamberlain corresponds to instant SEQ ID NO: 31 wherein Z1=N; J1=C; X1=Y; X2=T; X3=E; Z2=N; X4=L; X5=Q; X6=E; X7=M; X8=M; X9= N; Z3=K (also see page 37 of instant specification for instant SEQ ID NO: 31). Regarding claims 34-35, Chamberlain teaches “In one alternate embodiment, the IgG variant is conjugated or operably linked to another therapeutic compound” [0092]. Regarding claim 63, it is well known in the art that Fc region of antibody dimerizes and therefore variant Fc of Chamberlain comprising M252Y/S254T/T256E will also dimerize. Further, Fc of Chamberlain comprises Cysteine at position 220 which is responsible for disulfide bond in Fc dimer. Regarding claim 64, Chamberlain teaches a pharmaceutical composition [0184]. result 14 of 1.rag PNG media_image2.png 814 1090 media_image2.png Greyscale Claim Objection Claims 40 and 95 are objected to as being dependent from rejected base claim. Conclusion No claim is allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to CHEOM-GIL CHEONG whose telephone number is (571)272-6251. The examiner can normally be reached Monday - Friday 9:00 am - 5:00 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Misook Yu can be reached at 571-272-0839. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /CHEOM-GIL CHEONG/Examiner, Art Unit 1645 /MISOOK YU/Supervisory Patent Examiner, Art Unit 1641
Read full office action

Prosecution Timeline

Show 5 earlier events
Nov 10, 2025
Response after Non-Final Action
Nov 18, 2025
Non-Final Rejection (signed) — §102
Jan 05, 2026
Non-Final Rejection mailed — §102
May 05, 2026
Response Filed
Jun 04, 2026
Final Rejection mailed — §102
Sep 03, 2026
Request for Continued Examination
Sep 05, 2026
Response after Non-Final Action
Sep 21, 2026
Non-Final Rejection mailed — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12760115
ANTIBODIES AGAINST CLAUDIN 18.2 USEFUL IN CANCER DIAGNOSIS
2y 6m to grant Granted Oct 13, 2026
Patent 12746280
CHAGAS DISEASE VACCINE ANTIGENS WITH IMPROVED STABILITY AND DECREASED AGGREGATION
4y 5m to grant Granted Sep 29, 2026
Patent 12747289
MANUFACTURING METHODS FOR PRODUCING ANTI-IL12/IL23 ANTIBODY COMPOSITIONS
2y 8m to grant Granted Sep 29, 2026
Patent 12735487
MULTI-SPECIFIC ANTIBODIES AND METHODS OF MAKING AND USING THEREOF
6y 10m to grant Granted Sep 15, 2026
Patent 12734226
Injectable Botulinum Toxin Formulations And Methods Of Use Thereof Having Long Duration Of Therapeutic Or Cosmetic Effect
5y 0m to grant Granted Sep 15, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

5-6
Expected OA Rounds
64%
Grant Probability
99%
With Interview (+53.4%)
3y 4m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 194 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month